PHARNEXT: The latest results from CMTMe, a digital study evaluating the lifestyle of patients with Charcot-Marie-Tooth diseases (CMTs), will be presented at the 2023 Annual Meeting of the Peripheral Nerve Society (‘PNS’) – 14/ 06/2023 at 08:30

PARIS, France, June 14, 2023 at 8:30 a.m. (CET) – Pharnext SA (FR001400GUN7 – ALPHA)

(the “Company”), a late-stage biopharmaceutical company developing new therapies for neurodegenerative diseases with no satisfactory therapeutic solution, announces today that new results from ‘CMT&Me’, a digital study assessing the lifestyle of patients with Charcot-Marie-Tooth diseases (CMTs), will be presented in the form of two posters during the next annual congress of the

Peripheral Nerve Society

(PNS). This congress will be held from June 17 to 20, 2023 at the Bella Center Copenhagen in Copenhagen, Denmark.

CMT&Me is a digital study evaluating the lifestyle of patients with CMTs, launched in October 2018 in Europe and the United States for a period of 5 years. The study collects information provided directly by patients on a regular basis. Its objective is to better understand the impact of the disease on the daily life of patients and to help them manage their disease and their treatments. In addition, it also aims to educate various audiences about CMTs and help in the evaluation of new treatments. This study is being conducted by the Vitaccess company in collaboration with patient associations and CMT expert physicians, with the support of Pharnext.

Information on the posters presented during the PNS congress:

• Title
  
  :
  
  Patient-reported symptom severity of Charcot-Marie-Tooth disease type 1A: findings from a digital real-world study
  

To post:

P.29

Session:

Monday, June 19, 2023, 7:25 p.m.–8:25 p.m.

• Title: Patient-reported severity of lower extremity + upper limb disability in Charcot-Marie-Tooth disease type 1A: findings from a digital real-world study
  

To post:

P30

Session:

Monday, June 19, 2023, 7:25 p.m.–8:25 p.m.

During the PNS congress, the Pharnext team will be available for all discussions on stand n°24.

More information on the Congress: https://pnsociety.com/2023-annual-meeting/

More information on the CMT&Me study: https://clinicaltrials.gov/ct2/show/NCT03782883

About Pharnext

Pharnext is a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases that currently have no satisfactory therapeutic solution. Pharnext has a new drug candidate, PXT3003, in development for Charcot-Marie-Tooth disease type 1A (CMT1A), an inherited, rare and debilitating peripheral neuropathy. PXT3003 has orphan drug status in Europe and the United States. In 2018, PXT3003 completed a Phase III clinical study, the PLEO-CMT trial, with encouraging preliminary results. This trial was followed by an open-label extension study, the PLEO-CMT-FU trial, in which 120 patients are still currently continuing treatment with PXT3003. The long-term results suggest a sustained benefit, in terms of tolerance and efficacy, after a total clinical study period of 5 years. A pivotal international Phase III clinical study, the PREMIER trial, is ongoing, in which 387 patients with CMT1A have been enrolled. The first results of the PREMIER trial are expected in the fourth quarter of 2023. PXT3003 was discovered with the R&D approach of Pleotherapy™. Pharnext draws investors’ attention to the risk factors, particularly financial, detailed in its financial reports. More information on

www.pharnext.com

.

Pharnext is listed on the Euronext Growth market in Paris (ISIN code: FR001400GUN7).

contacts

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com